Ruxolitinib, a selective JAK1/JAK2 inhibitor, significantly alleviates palpable splenomegaly, ameliorated debilitating myelofibrosis‐related symptoms, and improved OS compared with placebo. Here, JAK2 is linked to myelofibrosis.